JP2013522230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522230A5 JP2013522230A5 JP2012557260A JP2012557260A JP2013522230A5 JP 2013522230 A5 JP2013522230 A5 JP 2013522230A5 JP 2012557260 A JP2012557260 A JP 2012557260A JP 2012557260 A JP2012557260 A JP 2012557260A JP 2013522230 A5 JP2013522230 A5 JP 2013522230A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lower alkyl
- methoxy
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000030266 primary brain neoplasm Diseases 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 101710152983 Beta-2 adrenergic receptor Proteins 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 0 C*(C)c1ccc(*)cc1 Chemical compound C*(C)c1ccc(*)cc1 0.000 description 18
- NMCQISYZJJUMBB-UHFFFAOYSA-N CC(C)c(cc(c1c2cccc1)OC)c2OC Chemical compound CC(C)c(cc(c1c2cccc1)OC)c2OC NMCQISYZJJUMBB-UHFFFAOYSA-N 0.000 description 2
- JFQYSUIAIZPZGB-UHFFFAOYSA-N CNc1c(ccc(OC)c2)c2ccc1 Chemical compound CNc1c(ccc(OC)c2)c2ccc1 JFQYSUIAIZPZGB-UHFFFAOYSA-N 0.000 description 2
- -1 aminocarbonyl (carbamoyl) Chemical group 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31264210P | 2010-03-10 | 2010-03-10 | |
| US61/312,642 | 2010-03-10 | ||
| PCT/US2011/027988 WO2011112867A1 (en) | 2010-03-10 | 2011-03-10 | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522230A JP2013522230A (ja) | 2013-06-13 |
| JP2013522230A5 true JP2013522230A5 (enExample) | 2014-04-17 |
| JP5837890B2 JP5837890B2 (ja) | 2015-12-24 |
Family
ID=43858307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557260A Active JP5837890B2 (ja) | 2010-03-10 | 2011-03-10 | 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9492405B2 (enExample) |
| EP (1) | EP2544676B1 (enExample) |
| JP (1) | JP5837890B2 (enExample) |
| AU (2) | AU2011224241B2 (enExample) |
| BR (1) | BR112012022552A8 (enExample) |
| CA (1) | CA2791702C (enExample) |
| WO (1) | WO2011112867A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6130495B2 (ja) | 2012-05-25 | 2017-05-17 | アメリカ合衆国 | カンナビノイド受容体活性関連障害及び疾患を調節する方法 |
| WO2015153719A2 (en) * | 2014-04-03 | 2015-10-08 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating breast cancer |
| CA2944743A1 (en) * | 2014-04-03 | 2015-10-08 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating melanoma |
| KR101585619B1 (ko) * | 2014-11-20 | 2016-01-15 | 주식회사 아모텍 | 감전보호소자 및 이를 구비한 휴대용 전자장치 |
| US20180042867A1 (en) * | 2015-03-06 | 2018-02-15 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating cancer |
| US20180271808A1 (en) * | 2015-10-01 | 2018-09-27 | Mitchell Woods Pharmaceuticals, Inc. | Methods of reducing chemoresistance and treating cancer |
| WO2017070052A1 (en) * | 2015-10-18 | 2017-04-27 | Onco Therapies Llc | Compositions and methods of regulating cancer related disorders and diseases |
| EP3490581A4 (en) * | 2016-07-26 | 2020-10-14 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED CANCER TREATMENT METHODS |
| GB201714736D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| CN109942462B (zh) * | 2019-03-06 | 2022-01-14 | 宏冠生物药业有限公司 | 一种盐酸班布特罗的合成工艺 |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| CN114456078B (zh) * | 2022-01-19 | 2022-09-16 | 汉瑞药业(荆门)有限公司 | 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE635889A (enExample) | ||||
| SE354279B (enExample) | 1969-06-13 | 1973-03-05 | Draco Ab | |
| CH556323A (de) | 1969-12-12 | 1974-11-29 | Boehringer Sohn Ingelheim | Verfahren zur herstellung von neuen naphthylalkylaminen. |
| DE1962497C3 (de) | 1969-12-12 | 1979-09-20 | C.H. Boehringer Sohn, 6507 Ingelheim | Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel |
| DE2010883A1 (de) | 1970-03-07 | 1971-09-23 | Troponwerke Dinklage & Co, 5000 Köln-Mülheim | Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung |
| AT308139B (de) | 1970-07-27 | 1973-06-25 | Degussa | Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen |
| IT1044214B (it) | 1971-04-22 | 1980-03-20 | Zambeletti Spa L | 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione |
| JPS532194B2 (enExample) | 1973-08-10 | 1978-01-26 | ||
| US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
| US6866839B2 (en) | 1991-04-05 | 2005-03-15 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| JPH07505887A (ja) | 1992-04-17 | 1995-06-29 | アボツト・ラボラトリーズ | タキソール誘導体 |
| AU4408897A (en) | 1996-07-05 | 1998-02-02 | E.C. Pesterfield Associates, Inc. | Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists |
| US6015837A (en) | 1996-08-29 | 2000-01-18 | New York Medical College | Method for treating scoliosis with β2-adrenoceptor agonists |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| WO1999016430A1 (en) | 1997-09-30 | 1999-04-08 | E.C. Pesterfield Associates, Inc. | Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists |
| ZA994264B (en) | 1998-07-01 | 2000-01-25 | Warner Lambert Co | Stereoisomers with high affinity for adrenergic receptors. |
| WO2000018389A2 (en) | 1998-09-30 | 2000-04-06 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | USE OF A β2 ADRENERGIC RECEPTOR AGONIST IN THE TREATMENT OF CARDIOVASCULAR DISEASE |
| CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| PT1506203E (pt) | 2002-08-23 | 2007-04-30 | Sloan Kettering Inst Cancer | Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações |
| US20050107417A1 (en) | 2003-07-28 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a novel anticholinergic and a betamimetic |
| DE602004016547D1 (de) | 2003-11-03 | 2008-10-23 | Myogen Inc | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen |
| US20060030611A1 (en) | 2004-03-22 | 2006-02-09 | Myogen, Inc. | Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases |
| US20080221203A1 (en) | 2004-08-09 | 2008-09-11 | University Catholique De Louvain | Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease |
| CN101137625A (zh) | 2005-01-11 | 2008-03-05 | 葛兰素集团有限公司 | β2肾上腺素能激动剂的肉桂酸盐 |
| CA2660707C (en) | 2006-08-10 | 2014-07-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
| TW200922547A (en) | 2007-10-02 | 2009-06-01 | Paer Johansson | Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on α-adrenergic and/or β-adrenergic receptors of the sympathetic nervous system, related to improved clot strength |
| CN102740895B (zh) * | 2009-12-23 | 2016-02-24 | 伊利诺伊大学董事会 | 纳米轭合物以及纳米轭合物配制品 |
-
2011
- 2011-03-10 WO PCT/US2011/027988 patent/WO2011112867A1/en not_active Ceased
- 2011-03-10 BR BR112012022552A patent/BR112012022552A8/pt not_active IP Right Cessation
- 2011-03-10 AU AU2011224241A patent/AU2011224241B2/en active Active
- 2011-03-10 CA CA2791702A patent/CA2791702C/en active Active
- 2011-03-10 US US13/583,206 patent/US9492405B2/en active Active
- 2011-03-10 EP EP11708381.6A patent/EP2544676B1/en active Active
- 2011-03-10 JP JP2012557260A patent/JP5837890B2/ja active Active
-
2014
- 2014-08-08 AU AU2014210656A patent/AU2014210656B2/en active Active
-
2016
- 2016-09-22 US US15/273,147 patent/US10130594B2/en active Active
-
2018
- 2018-09-12 US US16/129,470 patent/US10617654B2/en active Active
-
2020
- 2020-03-02 US US16/806,659 patent/US10925840B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522230A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| JP2013544887A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2013542261A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JPS62249923A (ja) | パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法 | |
| JP2014528901A5 (enExample) | ||
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2014505107A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2015519347A5 (enExample) | ||
| JP2010516702A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| JP2019520344A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2015500223A5 (enExample) |